A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Ohmachi, K; Kinoshita, T; Tobinai, K; Ogawa, G; Mizutani, T; Yamauchi, N; Fukuhara, N; Uchida, T; Yamamoto, K; Miyazaki, K; Tsukamoto, N; Iida, S; Utsumi, T; Yoshida, I; Imaizumi, Y; Tokunaga, T; Yoshida, S; Masaki, Y; Murayama, T; Yakushijin, Y; Suehiro, Y; Nosaka, K; Dobashi, N; Kuroda, J; Takamatsu, Y; Maruyama, D; Ando, K; Ishizawa, K; Ogura, M; Yoshino, T; Hotta, T; Tsukasaki, K; Nagai, H

Ohmachi, K (corresponding author), Tokai Univ, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.

BLOOD ADVANCES, 2021; 5 (4): 984

Abstract

Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索